Donor T Cells May Enhance Immunotherapy.
A proof-of-principle study demonstrates that T cells from healthy donors recognize many tumor neoantigens overlooked by a patient's own immune system. Outsourcing neoantigen-induced immune reactivity to donor T cells could be a feasible way to bolster patients' response to immunotherapy.